The Technical AnalystExchange: NSE Sector: Healthcare Industry: Drug Manufacturers—Specialty & Generic
Suven Pharmaceuticals Price, Forecast, Insider, Ratings, Fundamentals & Signals
-1.94% INR653.10
America/New_York / 8 mai 2024 @ 06:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 166 256 mill |
| EPS: | 14.57 |
| P/E: | 44.82 |
| Earnings Date: | May 23, 2024 |
| SharesOutstanding: | 254.57 mill |
| Avg Daily Volume: | 0.472 mill |
| RATING 2024-05-08 |
|---|
| A+ |
| Strong Buy |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Buy | |
| Return On Equity: | Buy | |
| Return On Asset: | Strong Buy | |
| DE: | Sell | |
| P/E: | Strong Buy | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | n/a | n/a | n/a | |||
| Debt | n/a | n/a | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE 44.82 | sector: PE 0 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0x |
| Company: PE 44.82 | industry: PE 0 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
INR588.36 (-9.91%) INR-64.74 |
| Date: 2024-05-08 |
| Expected Trading Range (DAY) |
|---|
|
INR 628.49 - 677.71 ( +/- 3.77%) |
| ATR Model: 14 days |
Live Trading Signals (every 1 min)
10.00
Buy
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | INR653.10 (-1.94% ) |
| Volume | 0.122 mill |
| Avg. Vol. | 0.472 mill |
| % of Avg. Vol | 25.90 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For SUVENPHAR.NS
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
SUVENPHAR.NS
Suven Pharmaceuticals Limited operates as a bio-pharmaceutical company in India, the United States, Europe, and internationally. It develops, manufactures, and sells new chemical entity-based intermediates, active pharmaceutical ingredients, specialty chemicals, and formulated drugs under contract research and manufacturing services for pharmaceutical, biotechnology, and chemical companies. The company was incorporated in 2018 and is headquartered in Hyderabad, India. Suven Pharmaceuticals Limited is a subsidiary of Jasti Property and Equity Holdings Private Limited.